Organon Submitting Remeron Pediatric Data To Congress
This article was originally published in The Pink Sheet Daily
Executive Summary
Organon is preparing its response to congressional investigators looking into the handling of pediatric research for antidepressants, the company said during a July 19 conference call
You may also be interested in...
Antidepressant Safety Concerns Not Impacting Forest's SSRI Sales
Publicity surrounding the safety of antidepressants in adult and pediatric patients is not having an impact on Forest's sales of Lexapro and Celexa, President Kenneth Goodman said during a July 20 conference call
Antidepressant Safety Concerns Not Impacting Forest's SSRI Sales
Publicity surrounding the safety of antidepressants in adult and pediatric patients is not having an impact on Forest's sales of Lexapro and Celexa, President Kenneth Goodman said during a July 20 conference call
GSK Handling Of Paxil Data On Pediatric Use Is Subject Of N.Y. Lawsuit
The state attorney general alleges that GSK failed to publish information about the safety and efficacy of Paxil in children. The lawsuit seeks disgorgement of profits. GSK maintains that it has publicly communicated the data from its pediatric studies.